The oral BTK* inhibitor evobrutinib at a dose of 75 mg/day reduced the number of gadolinium-enhancing lesions in patients with relapsing multiple sclerosis (MS), according to a phase II trial presented at AAN 2019.
A new orally dissolving tablet (ODT) formulation of rimegepant showed rapid onset of action and sustained benefits in terms of pain relief and symptom improvement in patients with acute migraine, the 303 study finds.
A novel three-drug cocktail, PXT3003, reduces disability in patients with Charcot-Marie-Tooth Type 1A disease (CMT1A) along with a favourable safety profile, according to the PLEO-CMT study presented at AAN 2019, providing hope for a rare disease which so far has no cure.
The terminal complement inhibitor eculizumab significantly lowered relapse risk in patients with neuromyelitis optical spectrum disorder (NMOSD) who were positive for aquaporin-4 antibodies (AQP4-IgG) compared with placebo, according to the PREVENT* study presented at AAN 2019.
A 10 or 20 mg/kg daily dose of cannabidiol could almost halve the risk of seizures in children with Dravet syndrome, according to the phase III GWPCARE2* study presented at the American Academy of Neurology annual meeting (AAN 2019).
Use of the antihypertensive drug isradipine did not reduce the progression of Parkinson’s disease, according to the STEADY-PD III* study presented at the American Academy of Neurology annual meeting (AAN 2019).
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacist - Malaysia digital copy today!
Elvira Manzano, Roshini Claire Anthony,
01 Oct 2019
The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.
Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US.
Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]